Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.6.2807

Toll-like Receptor 5 Agonist Inhibition of Growth of A549 Lung Cancer Cells in Vivo in a Myd88 Dependent Manner  

Zhou, Shi-Xiang (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Li, Feng-Sheng (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Qiao, Yu-Lei (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Zhang, Xue-Qing (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Wang, Zhi-Dong (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.6, 2012 , pp. 2807-2812 More about this Journal
Abstract
The purpose of this study was to examine the effect of a Toll-like receptor 5 (TLR5) agonist, CBLB502, on the growth and radiosensitivity of A549 lung cancer cells in vivo. Expression of myeloid differentiation factor 88 (MyD88) or TLR5 was stably knocked down in human lung cancer cells (A549) using lentivirus expressing short hairpin RNA targeting human MyD88 or TLR5. Lack of MyD88 or TLR5 expression enhanced tumor growth in mouse xenografts of A549 lung cancer cells. CBLB502 inhibited the growth of A549 lung cancer cells, not A549-MyD88-KD cells in vivo in the murine xenograft model. Our results showed that the inhibition of A549 by CBLB502 in vivo was realized through regulating the expression of neutrophil recruiting cytokines and neutrophil infiltration. Finally, we found that activation of TLR5 signaling did not affect the radiosensitivity of tumors in vivo.
Keywords
TLR5 agonist; CBLB502; tumor suppressor; lung cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Tse BW, Russell PJ, Lochner M, Forster I, Power CA (2011). IL- 18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS ONE, 6, e24241.   DOI
2 Wolska A, Lech-Maranda E, Robak T (2009). Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett, 14, 248-72.   DOI
3 Xie Q, Gan L, Wang J, Wilson I, Li L (2007). Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol, 44, 3453-61.   DOI
4 Zhang Y, Luo F, Cai Y, et al (2011). TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol, 186, 1963-9.   DOI
5 Zhang Y, Sun R, Liu B, et al (2009). TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol Ther, 8, 1826-30.   DOI
6 Armant MA, Fenton MJ (2002). Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol, 3, REVIEWS3011.
7 Bickels J, Kollender Y, Merinsky O, Meller I (2002). Coley's toxin: historical perspective. Isr Med Assoc J, 4, 471-2.
8 Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30   DOI
9 Challacombe JM, Suhrbier A, Parsons PG, et al (2006). Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol, 177, 8123-32.   DOI
10 Cheng YS, Xu F (2011). Anticancer function of polyinosinicpolycytidylic acid. Cancer Biol Ther, 10, 1219-23.
11 Di CE, Forni G, Lollini P, et al (2001). The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 97, 339-45.   DOI
12 Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med, 13, 552-9.   DOI   ScienceOn
13 Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL (2001). Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol, 167, 1882-5.   DOI
14 Hartman ZC, Osada T, Glass O, et al (2010). Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res, 70, 7209-20.   DOI
15 Hicks AM, Riedlinger G, Willingham MC, et al (2006). Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA, 103, 7753-8.   DOI
16 Lin YS, Huang LD, Lin CH, et al (2011). In vitro and in vivo anticancer activity of a synthetic glycolipid as TLR4 activator. J Biol Chem, (in press).
17 Kawai T, Akira S (2006). TLR signaling. Cell Death Differ, 13, 816-25.   DOI
18 Kawai T, Akira S (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 11, 373-84.   DOI
19 Khoo JJ, Forster S, Mansell A (2011). Toll-like receptors as interferon-regulated genes and their role in disease. J Interferon Cytokine Res, 31, 13-25.   DOI
20 Narayanan P, Lapteva N, Seethammagari M, et al (2011). A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest, 121, 1524-34.   DOI
21 Rhee SH, Im E, Riegler M, et al (2005). Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA, 102, 13610-5.   DOI
22 Nozawa H, Chiu C, Hanahan D (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA, 103, 12493-8.   DOI
23 Ostberg JR, Ertel BR, Lanphere JA (2005). An important role for granulocytes in the thermal regulation of colon tumor growth. Immunol Invest, 34, 259-72.   DOI
24 Rhee SH, Im E, Pothoulakis C (2008). Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology, 135, 518-28.   DOI
25 Rhee SH, Kim H, Moyer MP, Pothoulakis C (2006). Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem, 281, 18560-8.   DOI
26 Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006). TLR3 can directly trigger apoptosis in human cancer cells. J Immunol, 176, 4894-901.   DOI
27 Thomas JA, Badini M (2011). The role of innate immunity in spontaneous regression of cancer. Indian J Cancer, 48, 246-51.   DOI